SEC Filing Summary: Celsion Corporation (10-Q)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Celsion Corporation for the period ended June 30, 2001. The company is a biotechnology firm focused on developing thermotherapy systems for cancer and other diseases. As of the filing date (August 14, 2001), the company had 76,746,609 shares of Common Stock outstanding. The company has incurred substantial operating losses since inception and expects these losses to continue as it pursues clinical trials and regulatory approvals for new products.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2001 |
Nine Months Ended June 30, 2001 |
Nine Months Ended June 30, 2000 |
|---|---|---|---|
| Total Revenue | $1,462 | $3,320 | $3,465 |
| Net Loss | $(1,616,619) | $(4,569,626) | $(2,879,498) |
| Loss Per Share (Basic) | $(0.02) | $(0.06) | $(0.05) |
| Operating Expenses | $1,680,519 | $4,842,790 | $3,092,945 |
| Cash and Equivalents (End of Period) | $4,630,147 (as of June 30, 2001) | ||
| Working Capital | |||
| Accumulated Deficit | $(31,017,043) |
Material Changes vs. Prior Period
- Revenue: Revenue for the three months ended June 30, 2001, was $1,462 compared to $0 in the prior year quarter. For the nine-month period, revenue decreased slightly to $3,320 from $3,465 in the prior year. The company notes no significant new product revenue is expected until regulatory approvals are obtained.
- Operating Expenses: General and administrative expenses increased significantly by 145% ($667,352) for the quarter and 150% ($1.8 million) for the nine-month period. This was driven by increased staff, consulting, legal fees, and office expansion. Research and development expenses decreased by 14% for the quarter and 4% for the nine-month period, primarily due to a large one-time licensing payment in the prior year.
- Liquidity: Cash and cash equivalents decreased from $8,820,196 at September 30, 2000, to $4,630,147 at June 30, 2001. Net cash used in operating activities was $4,283,717 for the nine months ended June 30, 2001.
Outlook, Risks, and Contingencies
- Outlook: The company expects to expend approximately $7 million for the full fiscal year 2001, with about $4.3 million already spent. It anticipates meeting funding needs for the remainder of the fiscal year from current resources but acknowledges a continued dependence on raising additional capital.
- Risks: The company faces risks related to the success of clinical trials (currently in pivotal Phase II for breast cancer and BPH systems), obtaining FDA approvals, and the ability to secure future financing. If adequate funds are not available, the company may need to delay or scale back operations.
- Legal Proceedings: The company is involved in litigation against former director Warren C. Stearns and affiliates regarding the rescission of warrants for approximately 4.1 million shares. The case was transferred to the Northern District of Illinois, with a hearing scheduled for August 15, 2001.
- Stock Issuances: During the quarter, the company issued 225,000 shares upon option exercise and 234,042 shares upon conversion of preferred stock.
Investor Verification Checklist
- Cash Runway: Verify if the remaining cash of ~$4.6 million is sufficient to fund the estimated $2.7 million remaining expenditure for fiscal year 2001 and subsequent operations.
- Clinical Trial Status: Confirm the progress and results of the pivotal Phase II clinical trials for the breast cancer and BPH treatment systems, as these are critical for future revenue.
- Legal Resolution: Monitor the outcome of the litigation against Warren C. Stearns regarding the 4.1 million warrants, as a loss could result in significant dilution.
- Capital Raising: Assess the company's ability to raise additional capital if current resources are depleted before commercialization.
- Expense Management: Review the justification for the 150% increase in general and administrative expenses and its impact on the burn rate.